To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Europe | European ＆ international partnerships | Brain | Diseases
Autism Research in Europe
EU-AIMS aims to identify markers of autism that would allow earlier and more accurate diagnosis and prognosis, and the development of new therapies.
There are no effective pharmacological therapies for the core symptoms of autism, and the biological understanding of autism is poor. Research is hampered by a lack of biological models and clinical trials with diverse groups of people with autism
While new treatments have been developed, there is no European platform to test them clinically. The recent identification of genes associated with autism offers unique opportunities to remedy this situation.
The EU-AIMS consortium aims to undertake an integrated, translational effort to achieve key objectives in autism research. We have provided new tools and standards for clinical development to pave the way for a better quality of life for people with autism.
We have sought to harness these new developments to develop treatments based on our biological understanding of autism.
Joliot Institute Contact: Vincent Frouin (firstname.lastname@example.org)
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.